Satiogen Pharmaceuticals
San Diego, California, United States
About Satiogen Pharmaceuticals
Satiogen Pharmaceuticals is a specialty pharma company focused on novel-target for treating type 2 diabetes. The company's metabolic mechanism therapy offers designed to regulate nutrient intake and postprandial glucose. The company's products include a substitute for metformin in gliptin formulations and an OTC nutraceutical that would reduce body weight and postprandial glucose, enabling doctors to treat type 2 diabetes and obesity without intervention.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Estimated revenue: $1K – $10K
- Total funding: $700.0K
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2008)
- Website: satiogen.com
Social Profiles
Canonical: https://fsome.com/organization/satiogen-pharmaceuticals-2500146 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.